Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

A Tale Of Two Committees: Which Probed EpiPen Better?

Executive Summary

If you were an FDA official, would you prefer to be a sideshow at a contentious House committee hearing or the focus of a cordial Senate one?


Related Content

FDA Hiring Campaign Continues; Goal Is Addressing Pending ANDAs
EpiPen Price Hearing: House Plays Bootleg Tape Of Shkreli Event
EpiPen Generics: Woodcock Explains Injector Studies
Mylan's EpiPen Nightmare Not Over Yet, But Will Congress Just Write?
Why Generic EpiPen Is Not The Answer – Until FDA Says It Is


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst